- ICH GCP
- Реестр клинических исследований США
- Клиническое испытание NCT07909200
Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder (TIs-GAD)
Temporal Interference Transcranial Alternating Current Stimulation Targeting the BNST or Amygdala for Generalized Anxiety Disorder: A Randomized Controlled Trial
This randomized controlled trial will use a three-arm, parallel-group design to evaluate the efficacy and safety of 5-Hz Temporal Interference transcranial Alternating Current Stimulation (TI-tACS) in adults with generalized anxiety disorder (GAD). A total of 75 participants will be randomized in a 1:1:1 ratio to receive stimulation targeting the right bed nucleus of the stria terminalis (BNST), stimulation targeting the right amygdala, or sham stimulation. Participants will receive three 20-minute sessions per day, with 1-hour intervals between sessions, for 7 consecutive days (21 sessions in total). The primary outcome is the change in Hamilton Anxiety Rating Scale (HAMA) total score from baseline to Week 1. Secondary and exploratory assessments will include clinical symptoms, intolerance of uncertainty and related cognitive characteristics, treatment tolerability, adverse events, and EEG and MRI measures. Follow-up assessments will be conducted at Week 1, Week 4, and Week 8 from baseline to assess the durability of clinical effects and safety.
Обзор исследования
Статус
Подробное описание
Generalized anxiety disorder (GAD) is characterized by persistent and excessive anxiety and worry. Intolerance of uncertainty is an important cognitive feature associated with pathological worry. The amygdala and bed nucleus of the stria terminalis (BNST) contribute to threat processing, with evidence suggesting differences in their responses to brief and sustained threats. Comparing interventions targeting these regions may help clarify their contributions to anxiety symptoms, intolerance of uncertainty, and persistent worry.
Temporal interference stimulation uses two kilohertz-frequency alternating currents with a small frequency difference to generate an amplitude-modulated electric field envelope at the difference frequency. This study will compare right BNST-targeted and right amygdala-targeted stimulation using a 5-Hz envelope, with sham stimulation as the control.
Individualized head models will be constructed from each participant's T1-weighted magnetic resonance images. Electric field modeling will guide scalp electrode placement for the assigned target. Stimulation intensity will be individually adjusted according to participant tolerability within a range of 1.5-3.5 mA per channel, expressed as zero-to-peak amplitude.
Electroencephalography and magnetic resonance imaging will be used to investigate changes in theta-band activity and functional connectivity within anxiety-related networks. Associations between these changes and improvements in clinical symptoms and cognitive measures will be examined to explore the neural mechanisms of stimulation at the two targets. Peripheral blood samples will be collected at baseline, Week 1, and Week 8 and stored for future exploratory biomarker analyses related to GAD and treatment response.
Тип исследования
Регистрация (Оцененный)
Фаза
- Непригодный
Контакты и местонахождение
Контакты исследования
- Имя: Yumeng Ju, PhD
- Номер телефона: 86+18100731091
- Электронная почта: yumeng.ju@csu.edu.cn
Учебное резервное копирование контактов
- Имя: Xueting Li, PhD Candidate
- Электронная почта: 2458261900@qq.com
Места учебы
-
-
Fujian
-
Fuzhou, Fujian, Китай
- Рекрутинг
- Neuropsychiatric Prevention and Treatment Hospital of Fuzhou Second General Hospital
-
Контакт:
- Xueting Li
- Номер телефона: 86+13956590989
- Электронная почта: 2458261900@qq.com
-
-
Hunan
-
Changsha, Hunan, Китай
- Рекрутинг
- Second Xiangya Hospital of Central South University
-
Контакт:
- Hui Liang
- Номер телефона: 86+13876220412
- Электронная почта: 1136293417@qq.com
-
Changsha, Hunan, Китай
- Еще не набирают
- Brain Hospital of Hunan Province (Hunan Second People's Hospital)
-
Контакт:
- Wenwen Ou
- Номер телефона: 86+15116200923
- Электронная почта: TIassistant701@163.com
-
-
Jiangsu
-
Yangzhou, Jiangsu, Китай
- Рекрутинг
- Jiangsu Yangzhou Wutaishan Hospital
-
Контакт:
- Jinrong Sun
- Номер телефона: 86+13813176637
- Электронная почта: 1723487395@qq.com
-
-
Критерии участия
Критерии приемлемости
Возраст, подходящий для обучения
Принимает здоровых добровольцев
Полы, имеющие право на обучение
Описание
Inclusion Criteria:
- Aged 18 to 55 years, inclusive, of any sex;
- Diagnosis of generalized anxiety disorder (GAD) according to DSM-5 criteria, assessed by trained researchers using the Structured Clinical Interview for DSM-5 (SCID), without psychotic features;
- Hamilton Anxiety Rating Scale (HAMA) total score of 14 or higher at screening;
- Has completed at least junior high school education and has sufficient hearing, reading, writing, and comprehension abilities to complete study assessments;
- Is willing and able to provide written informed consent and comply with study visits, treatment procedures, laboratory tests, and other study requirements.
Exclusion Criteria:
- Participants with a current or previous diagnosis of a major psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), such as schizophrenia spectrum and other psychotic disorders or bipolar and related disorders;
- Pregnancy or lactation;
- Neurologic disorders or serious systemic diseases (e.g., thyroid disease, lupus erythematosus, diabetes, hepatic or renal impairment, active infection, major trauma);
- History of significant head injury or coma;
- Received any standardized neuromodulation therapy targeting the nervous system within the past 6 months before enrollment, including but not limited to electroconvulsive therapy (ECT), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), or vagus nerve stimulation (VNS);
- Suspected or confirmed history of alcohol or substance dependence;
- Current severe suicidal ideation or recent suicide attempt;
- Current participation in another clinical trial or recent use of prohibited psychotropic medications;
- Positive urine drug screening or abnormal thyroid function tests;
- Contraindications to magnetic resonance imaging (MRI) or electroencephalography (EEG);
- Inability to provide fully informed consent.
Учебный план
Как устроено исследование?
Детали дизайна
- Основная цель: Уход
- Распределение: Рандомизированный
- Интервенционная модель: Параллельное назначение
- Маскировка: Четырехместный
Оружие и интервенции
Группа участников / Армия |
Вмешательство/лечение |
|---|---|
|
Экспериментальный: Right BNST-targeted TI-tACS
Participants will receive 5-Hz temporal interference stimulation targeting the right bed nucleus of the stria terminalis (BNST), for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions. |
Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right BNST, through the interaction of two currents (2000 Hz, 2005Hz). Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right Amygdala, through the interaction of two currents (2000 Hz, 2005Hz) |
|
Экспериментальный: Right Amygdala-targeted TI-tACS
Participants will receive 5-Hz temporal interference stimulation targeting the right amygdala, for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions. |
Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right BNST, through the interaction of two currents (2000 Hz, 2005Hz). Temporal Interference Transcranial Alternating Current Stimulation (TI-tACS) is a non-invasive neuromodulation technique that generates an envelope field (particularly 5 Hz) in deep brain regions, particularly the right Amygdala, through the interaction of two currents (2000 Hz, 2005Hz) |
|
Фальшивый компаратор: Sham TI-tACS
Participants will receive sham temporal interference stimulation, for 20 minutes per session, three sessions per day with 1-hour intervals, for 7 consecutive days, for a total of 21 sessions. |
Sham Temporal Interference transcranial Alternating Current Stimulation will mimic the sensory experience of active stimulation without delivering effective current. |
Что измеряет исследование?
Первичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score From Baseline to Week 1
Временное ограничение: Baseline and Week 1
|
Anxiety severity will be evaluated using the Hamilton Anxiety Rating Scale (HAMA), a clinician-administered instrument comprising 14 items. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. The outcome is the change in HAMA total score from baseline to Week 1. |
Baseline and Week 1
|
Вторичные показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Clinical Response Rate
Временное ограничение: Week 1, Week 4, and Week 8
|
Clinical response will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical response is defined as a reduction of at least 50% in HAMA total score compared with baseline. |
Week 1, Week 4, and Week 8
|
|
Clinical Remission Rate
Временное ограничение: Week 1, Week 4, and Week 8
|
Clinical remission will be assessed using the Hamilton Anxiety Rating Scale (HAMA), a 14-item clinician-administered scale with a total score range of 0 to 56. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. Clinical remission is defined as a HAMA total score of 7 or less at the corresponding assessment time point. |
Week 1, Week 4, and Week 8
|
|
Change in Hamilton Anxiety Rating Scale (HAMA) Total Score
Временное ограничение: Baseline, Week 1, Week 4, and Week 8
|
Anxiety severity will be evaluated using the Hamilton Anxiety Rating Scale (HAMA), a clinician-administered instrument comprising 14 items. Total scores range from 0 to 56, with higher scores indicating more severe anxiety symptoms. The outcome is the change in HAMA total score from baseline to each subsequent assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in 17-item Hamilton Depression Rating Scale (HAMD-17) Total Score
Временное ограничение: Baseline, Week 1, Week 4, and Week 8
|
Depressive symptom severity will be assessed using the 17-item Hamilton Depression Rating Scale (HAMD-17), a clinician-administered scale with a total score range of 0 to 52. Higher scores indicate greater depressive symptom severity, which represents a worse outcome. The outcome will be calculated as the change in HAMD-17 total score from baseline to each post-baseline assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in Generalized Anxiety Disorder-7 (GAD-7) Score
Временное ограничение: Baseline, Week 1, Week 4, and Week 8
|
Anxiety symptom severity will be assessed using the Generalized Anxiety Disorder-7 (GAD-7), a 7-item self-report questionnaire with a total score range of 0 to 21. Higher scores indicate greater anxiety symptom severity, which represents a worse outcome. The outcome will be calculated as the change in GAD-7 score from baseline to each post-baseline assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in Intolerance of Uncertainty Scale (IUS) Score
Временное ограничение: Baseline, Week 1, Week 4, and Week 8
|
Intolerance of uncertainty will be assessed using the Intolerance of Uncertainty Scale (IUS), a 27-item self-report questionnaire with a total score range of 27 to 135. Higher scores indicate greater intolerance of uncertainty, which represents a worse outcome. The outcome will be calculated as the change in IUS total score from baseline to each post-baseline assessment time point. |
Baseline, Week 1, Week 4, and Week 8
|
|
Change in Anxiety and Depression Visual Analogue Scale Scores
Временное ограничение: Baseline, Day 1, Week 1, Week 4, and Week 8
|
Subjective anxiety and depression severity will be assessed using visual analogue scale ratings for anxiety and depression. Each visual analogue scale score ranges from 0 to 10, with higher scores indicating greater subjective symptom severity, which represents a worse outcome. The outcome will be calculated as the change in visual analogue scale scores from baseline to each post-baseline assessment time point |
Baseline, Day 1, Week 1, Week 4, and Week 8
|
|
Treatment-Emergent Side Effects During the Intervention and Follow-up Period
Временное ограничение: Week 1, Week 4, and Week 8
|
Treatment-emergent side effects will be assessed using a physical treatment side-effect assessment that records the presence, type, severity, and relationship to the study intervention of adverse events. This outcome will be summarized as the occurrence and severity of treatment-emergent side effects during the intervention and follow-up period; higher severity indicates a worse safety outcome. |
Week 1, Week 4, and Week 8
|
Другие показатели результатов
Мера результата |
Мера Описание |
Временное ограничение |
|---|---|---|
|
Change in EEG Theta-Band Power
Временное ограничение: Baseline, Week 1, and Week 8
|
Brain electrophysiological activity will be assessed using electroencephalography (EEG). Theta-band power (4-8 Hz) will be assessed using EEG. The outcome will be calculated as the change in theta-band power from baseline to each post-baseline assessment. |
Baseline, Week 1, and Week 8
|
|
Change in Right Amygdala Seed-Based Resting-State Functional Connectivity
Временное ограничение: Baseline, Week 1, and Week 8
|
Resting-state functional magnetic resonance imaging (fMRI) will be used to assess functional connectivity between the right amygdala and other brain regions. Connectivity will be quantified using Fisher z-transformed Pearson correlation coefficients between regional blood oxygen level-dependent (BOLD) signal time series. Changes from baseline will be calculated at each post-baseline MRI assessment. |
Baseline, Week 1, and Week 8
|
|
Change in Right BNST Seed-Based Resting-State Functional Connectivity
Временное ограничение: Baseline, Week 1, and Week 8
|
Resting-state functional magnetic resonance imaging (fMRI) will be used to assess functional connectivity between the right bed nucleus of the stria terminalis (BNST) and other brain regions. Connectivity will be quantified using Fisher z-transformed Pearson correlation coefficients between regional blood oxygen level-dependent (BOLD) signal time series. Changes from baseline will be calculated at each post-baseline MRI assessment. |
Baseline, Week 1, and Week 8
|
|
Blinding Integrity at the End of Treatment
Временное ограничение: Week 1
|
Blinding integrity will be assessed using a brief questionnaire completed independently by participants and outcome assessors after the week 1 primary outcome assessment. Respondents will indicate whether they believe the participant received active stimulation, sham stimulation, or "do not know." They will also be asked to guess the specific treatment assignment: right BNST-targeted stimulation, right amygdala-targeted stimulation, sham stimulation, or "do not know." The reasons for their guesses will be recorded. The percentages of correct guesses, incorrect guesses, and "do not know" responses will be summarized by randomized group, separately for participants and outcome assessors. Actual treatment assignments will not be disclosed during this assessment. |
Week 1
|
Соавторы и исследователи
Спонсор
Соавторы
Следователи
- Учебный стул: Yan Zhang, PhD, Second Xiangya Hospital of Central South University
- Главный следователь: Yumeng Ju, PhD, Second Xiangya Hospital of Central South University
- Директор по исследованиям: Jiawu Ji, PhD, Neuropsychiatric Prevention and Treatment Hospital of Fuzhou Second General Hospital
Даты записи исследования
Изучение основных дат
Начало исследования (Действительный)
Первичное завершение (Оцененный)
Завершение исследования (Оцененный)
Даты регистрации исследования
Первый отправленный
Впервые представлено, что соответствует критериям контроля качества
Первый опубликованный (Действительный)
Обновления учебных записей
Последнее опубликованное обновление (Действительный)
Последнее отправленное обновление, отвечающее критериям контроля качества
Последняя проверка
Дополнительная информация
Термины, связанные с этим исследованием
Ключевые слова
Дополнительные соответствующие термины MeSH
Другие идентификационные номера исследования
- FZLL202651
Планирование данных отдельных участников (IPD)
Планируете делиться данными об отдельных участниках (IPD)?
Описание плана IPD
Individual participant data will not be shared because the dataset includes sensitive neuroimaging and biological data that may compromise participant confidentiality.
Информация о лекарствах и устройствах, исследовательские документы
Изучает лекарственный продукт, регулируемый FDA США.
Изучает продукт устройства, регулируемый Управлением по санитарному надзору за качеством пищевых продуктов и медикаментов США.
Эта информация была получена непосредственно с веб-сайта clinicaltrials.gov без каких-либо изменений. Если у вас есть запросы на изменение, удаление или обновление сведений об исследовании, обращайтесь по адресу register@clinicaltrials.gov. Как только изменение будет реализовано на clinicaltrials.gov, оно будет автоматически обновлено и на нашем веб-сайте. .